732 First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21–1480, an affinity-balanced PD-L1x4–1BBxHSA trispecific antibody: results of phase 1 dose escalation

Abstract

BackgroundNM21-1480 is a tri-specific Fc-lacking antibody that agonizes 4-1BB and blocks PD-L1/PD-1 signaling, designed to restrict activation of the 4-1BB pathway to the tumor microenvironment.1 NM21-1480 contains an ultra-potent PD-L1...